Span Divergent Secures BSE Approval for ₹5.79 Crore Share Issue

Span Divergent Ltd. is moving forward with a plan to issue equity shares worth ₹5.79 crore after receiving 'in-principle' approval from the BSE.

BSE Grants In-Principle Approval

The Bombay Stock Exchange (BSE) has given its 'in-principle' approval for Span Divergent Ltd. to issue 18,01,481 equity shares. These shares will be sold at ₹32.16 each, carrying a face value of ₹10, to Mr. Neev Nirav Jogani, who is not currently a promoter. The total capital to be raised through this preferential allotment is ₹5.79 crore. This approval is contingent on the company meeting all regulatory demands and completing necessary post-issue procedures.

Significance of the Share Issue

This share issuance serves as a capital infusion for Span Divergent Ltd., aiming to bolster its financial standing. It will also adjust the company's shareholding makeup, as Mr. Jogani acquires a stake. Investors will note this as a move to raise funds, with the identity of the allottee and the sale price offering insights into the deal's purpose.

Company Background

Span Divergent Ltd., previously known as Span Diagnostics Limited, has been a diversified holding company since its founding in 1972. After selling its in-vitro diagnostics (IVD) business in 2015, the company expanded into areas such as food, life sciences, and business consulting. As of March 2026, promoters held about 64% of the company's shares, with retail investors owning the remaining 36%. This recent filing marks a significant regulatory step following previous announcements of planned preferential issues.

Expected Changes

Following the allotment, Span Divergent Ltd.'s equity base will grow with the new shares. Mr. Neev Nirav Jogani will join the shareholder roster, altering the company's overall ownership structure. Span Divergent must then complete listing procedures for these shares. The funds secured are anticipated to strengthen the company's financial reserves.

Potential Risks

The company must navigate several risks, including strict adherence to regulations like the Companies Act and SEBI rules. Execution is another challenge, requiring the filing of a listing application and completion of post-issue formalities within twenty days of the share allotment. Mr. Jogani will need to provide an undertaking against intra-day trading or early sales before allotment. The BSE also retains the right to revoke its 'in-principle' approval if any provided information proves incomplete or false. Furthermore, obtaining all other required statutory approvals is essential. Investors should also note Span Divergent's history of poor sales growth over five years, a low interest coverage ratio, negative ROCE, and accumulated losses in some subsidiaries.

Industry Context

Span Divergent's diversified business model makes pinpointing direct industry peers challenging. While some segments overlap with food and life sciences, companies like Sun Pharma Industries Ltd. and Divi's Laboratories Ltd. operate on a much larger scale in the broader pharmaceutical sector. In the food sector, Patanjali Foods Ltd. may offer a tangential comparison.

Key Figures

The preferential issue is priced at ₹32.16 per equity share, a ₹22.16 premium over the ₹10 face value, as of March 19, 2026. The total size of the issue is ₹5.79 crore (₹579.01 lakh). A total of 18,01,481 equity shares will be issued.

Next Steps for Investors

Investors will be watching for the completion of the preferential share allotment to Mr. Neev Nirav Jogani. Key milestones include the filing of the listing application within twenty days after allotment and confirmation of compliance with all regulatory steps. Future announcements on how the raised funds will be used will also be important to monitor.